natural killer cell infusion

BIOLOGICAL5 trials

Sponsors

St. Jude Children's Research Hospital, Masonic Cancer Center, University of Minnesota, M.D. Anderson Cancer Center

Conditions

Acute Myeloid LeukemiaBreast CancerNeuroblastomaRecurrent B-Cell Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood B-Lymphoblastic Lymphoma

Phase 2

Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer

TerminatedNCT00376805

Masonic Cancer Center, University of MinnesotaBreast Cancer

Start: 2006-04-30End: 2010-01-31Updated: 2017-12-28

Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma

TerminatedNCT00698009

M.D. Anderson Cancer CenterNeuroblastoma

Start: 2008-06-30End: 2012-06-30Updated: 2020-09-24

Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

CompletedNCT01700946

St. Jude Children's Research HospitalRecurrent B-Cell Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood B-Lymphoblastic Lymphoma

Start: 2013-04-15End: 2021-07-24Updated: 2022-09-28

Therapy for Children With Advanced Stage Neuroblastoma

Active, not recruitingNCT01857934

St. Jude Children's Research HospitalNeuroblastoma

Start: 2013-07-05End: 2025-12-31Updated: 2025-11-17

Unknown Phase

Natural Killer (NK) Cell Transplantation for AML

CompletedNCT00187096

St. Jude Children's Research HospitalAcute Myeloid Leukemia

Start: 2005-09-30End: 2013-03-31Updated: 2014-06-19

Related Papers

Longitudinal NK cell kinetics and cytotoxicity in children with neuroblastoma enrolled in a clinical phase II trial

Journal for ImmunoTherapy of Cancer2020-03-0125 citations

Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma

Journal for ImmunoTherapy of Cancer2020-03-015 citations

Early response rates and Curie scores at end of induction: An update from a phase II study of an anti-GD2 monoclonal antibody (mAb) with chemotherapy (CT) in newly diagnosed patients (pts) with high-risk (HR) neuroblastoma (NB).

Journal of Clinical Oncology2017-05-2013 citations

Improved clinical responses with the concomitant use of an anti-GD2 monoclonal antibody and chemotherapy in newly diagnosed children with high-risk (HR) neuroblastoma (NB): Preliminary results of a phase II study.

Journal of Clinical Oncology2016-05-2014 citations